Goldman Sachs Starts Viela Bio (VIE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Starts Viela Bio (VIE) at Outperform
October 28, 2019 5:32 AM EDTCowen analyst Chris Shibutani initiates coverage on Viela Bio (NASDAQ: VIE) with a Outperform rating.
The analyst comments "We expect inebilizumab, VIEs clinically de-risked, late-stage lead asset, to gain approval (June 2020 PDUFA) and contend as a leading treatment for neuromyelitis optica (NMO),... More
